D. Boral Capital Reaffirms Buy Rating for Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a report issued on Thursday,Benzinga reports. They currently have a $36.00 target price on the biopharmaceutical company’s stock. D. Boral Capital’s price objective indicates a potential upside of 290.03% from the company’s current price.

OMER has been the topic of several other reports. StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. RODMAN&RENSHAW upgraded Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. Cantor Fitzgerald restated a “neutral” rating on shares of Omeros in a report on Thursday, November 14th. Rodman & Renshaw initiated coverage on shares of Omeros in a research note on Thursday, November 14th. They set a “buy” rating and a $9.00 price target for the company. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research note on Thursday, December 19th. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Omeros has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Trading Up 3.7 %

NASDAQ OMER traded up $0.33 during trading hours on Thursday, hitting $9.23. 381,579 shares of the company’s stock were exchanged, compared to its average volume of 636,787. Omeros has a 1-year low of $2.61 and a 1-year high of $13.60. The stock has a 50-day simple moving average of $9.15 and a 200 day simple moving average of $5.94. The firm has a market cap of $534.88 million, a price-to-earnings ratio of -4.00 and a beta of 2.01.

Institutional Investors Weigh In On Omeros

Institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp boosted its stake in shares of Omeros by 16.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock worth $887,000 after buying an additional 31,081 shares during the last quarter. Rhumbline Advisers boosted its position in Omeros by 6.1% in the second quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock worth $454,000 after purchasing an additional 6,435 shares during the last quarter. AQR Capital Management LLC bought a new position in Omeros in the 2nd quarter valued at $105,000. SG Americas Securities LLC bought a new position in Omeros in the 3rd quarter valued at $80,000. Finally, SPC Financial Inc. purchased a new stake in shares of Omeros during the 3rd quarter valued at $77,000. 48.79% of the stock is owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.